Trofinetide

What it's for

Trofinetide is a synthetic analog of glycine-proline-glutamate (GPE), a peptide fragment related to IGF-1 biology. It is approved in the U.S. for Rett syndrome.

What it does for the body

It is indicated to treat Rett syndrome, a rare neurodevelopmental disorder. It is not approved as a general cognitive enhancer or cognition-focused. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

Trofinetide is thought to gently adjust brain inflammation-related and nerve-connection pathways implicated in Rett syndrome models. The clinical effect is described in terms of pathway support rather than a single simple receptors (lock-and-key landing spots on cells) switch.

Research context

Bottom line for readers: Trofinetide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Brain research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Trofinetide — FDA.gov search
• ClinicalTrials.gov search: Trofinetide — U.S. clinical trials registry
• Drugs@FDA search: Trofinetide — FDA drug database (if approved)
• PubMed search: Trofinetide — NCBI PubMed
• PubMed Central search: Trofinetide — NCBI PMC

Reference

No ref on file.